<DOC>
	<DOCNO>NCT00684944</DOCNO>
	<brief_summary>This open label , dose-ranging study two dos TRx0014 patient mild moderate Alzheimer 's Disease . The trial make available patient ongoing treatment clinical trial designate TRx-014-001 termination study . Treatment individual patient continue long treat physician feel benefit patient . This current protocol cover patient 12 month first instance .</brief_summary>
	<brief_title>Open Label Study TRx0014 Alzheimer 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>The patient may either sex must supervise carer competent ensure compliance medication willing participate complete various assessment . The carer must provide write consent participation study . Patients capacity must give write informed consent participate study . Patients lack capacity consent must agreement enter study personal legal representative give write informed consent participation . The patient must ongoing TRx014001 time study termination . There exclusion criterion . All patient take medication termination study TRx014001 wish participate eligible recruitment .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2012</verification_date>
</DOC>